title: KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL.
abstract: We analyzed the influence of donor killer-cell immunoglobulin-like receptor (KIR) gene haplotypes on the risk for relapse and the probability of event-free survival (EFS) in children with acute lymphoblastic leukemia who received human leukocyte antigen-haploidentical transplantation of ex vivo T-cell-depleted peripheral blood stem cells. The KIR gene haplotype was evaluated in 85 donors, and the KIR B content score was determined in the 63 KIR haplotype B donors. Patients transplanted from a KIR haplotype B donor had a significantly better EFS than those transplanted from a KIR haplotype A donor (50.6% vs 29.5%, respectively; P = .033). Moreover, a high donor KIR B-content score was associated with a significantly reduced risk for relapse (Log-rank test for trend, P = .026). These data indicate that KIR genotyping should be included in the donor selection algorithm for haploidentical transplantation in children with acute lymphoblastic leukemia with the aim of choosing, whenever possible, a KIR haplotype B donor with a high KIR B-content score.
authors.affiliation: Children's Hospital, University of Tübingen, Germany;
authors.forename: Lena
authors.initials: L
authors.lastname: Oevermann
authors.affiliation: Children's Hospital, University of Tübingen, Germany;
authors.forename: Sebastian U
authors.initials: SU
authors.lastname: Michaelis
authors.affiliation: Children's Hospital, University of Tübingen, Germany;
authors.forename: Markus
authors.initials: M
authors.lastname: Mezger
authors.affiliation: Children's Hospital, University of Tübingen, Germany;
authors.forename: Peter
authors.initials: P
authors.lastname: Lang
authors.affiliation: Department of Pediatric Oncology, University Hospital Lund, Sweden;
authors.forename: Jacek
authors.initials: J
authors.lastname: Toporski
authors.affiliation: Department of Pediatric Hematology and Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Ospedale Pediatrico Bambino Gesù, Rome, University of Pavia, Italy;
authors.forename: Alice
authors.initials: A
authors.lastname: Bertaina
authors.affiliation: Pediatric Hematology/Oncology, Fondazione, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico, San Matteo, Pavia, Italy;
authors.forename: Marco
authors.initials: M
authors.lastname: Zecca
authors.affiliation: Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Giannina Gaslini, Department of Experimental Medicine and Center of Excellence for Biomedical Research, University of Genova, Italy.
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Moretta
authors.affiliation: Department of Pediatric Hematology and Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Ospedale Pediatrico Bambino Gesù, Rome, University of Pavia, Italy;
authors.forename: Franco
authors.initials: F
authors.lastname: Locatelli
authors.affiliation: Children's Hospital, University of Tübingen, Germany;
authors.forename: Rupert
authors.initials: R
authors.lastname: Handgretinger
mesh_terms: D000293:Adolescent; D001782:Blood Donors; D002648:Child; D002675:Child, Preschool; D046148:Donor Selection; D005260:Female; D005838:Genotype; D006239:Haplotypes; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local; D017063:Outcome Assessment, Health Care / Q000706:statistics & numerical data; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy*; D016016:Proportional Hazards Models; D054340:Receptors, KIR / Q000145:classification / Q000235:genetics*; D012307:Risk Factors
chemical_list: D054340:Receptors, KIR